Screener
Gilead Sciences GILD Biktarvy — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000882095-26-000031
| (in millions) | Three Months Ended June 30, 2026 / U.S. | Three Months Ended June 30, 2026 / Europe | Three Months Ended June 30, 2026 / Rest of World | Three Months Ended June 30, 2026 / Total | Three Months Ended June 30, 2025 / U.S. | Three Months Ended June 30, 2025 / Europe | Three Months Ended June 30, 2025 / Rest of World | Three Months Ended June 30, 2025 / Total |
|---|---|---|---|---|---|---|---|---|
| Product sales: | ||||||||
| HIV | ||||||||
| Biktarvy | $2,981 | $468 | $323 | $3,772 | $2,799 | $429 | $302 | $3,530 |
| Descovy | 921 | 23 | 23 | 967 | 601 | 24 | 28 | 653 |
| Genvoya | 236 | 37 | 16 | 289 | 322 | 40 | 16 | 377 |
| Odefsey | 171 | 58 | 10 | 239 | 221 | 66 | 11 | 298 |
| Symtuza - Revenue share(1) | 105 | 30 | 3 | 138 | 88 | 33 | 3 | 124 |
| Yeztugo | 223 | — | 9 | 232 | 15 | — | — | 15 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Gilead Sciences's biktarvy — total revenues?
- Gilead Sciences (GILD) reported biktarvy — total revenues of $3.77B in Q2 2026.
- How has Gilead Sciences's biktarvy — total revenues changed year-over-year?
- Gilead Sciences's biktarvy — total revenues increased by 6.9% year-over-year, from $3.53B to $3.77B.
- What is the long-term trend for Gilead Sciences's biktarvy — total revenues?
- Over 4 years (2021 to 2025), Gilead Sciences's biktarvy — total revenues has grown at a 13.5% compound annual growth rate (CAGR), from $8.62B to $14.33B.
- What does biktarvy — total revenues mean?
- This metric represents the total gross revenue generated from the sales of a specific flagship HIV treatment product line. It reflects the market adoption, pricing power, and clinical demand for this therapeutic asset within the company's broader infectious disease portfolio. As a primary revenue driver, it serves as a key indicator of the company's competitive positioning in the antiviral market.
Ask your AI about Gilead Sciences's biktarvy — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude